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Running title: 
Bilineal leukemia 
 
The association of chronic lymphocytic leukemia (CLL) and acute leukemia (AL) is rare. [1]. 
In most cases, AL develops after treatment of CLL, thus, previous chemotherapy or 
radiotherapy is usually considered as a leukemogenic event [2].  
We report two cases of acute leukemia occurring in patients with untreated chronic 
lymphocytic leukemia with remarkably similar time cluster.  Those two ALs had the same 
morphological but distinct immunophenotypic features.  
The first patient was a 55-year-old woman. The diagnosis of CLL was made in 1998 when a 
hematologic work-up was consistent with B-cell CLL, Rai stage 1 [3], and a low tumor 
burden by TTM classification [4]. Clinical course was stable, and the patient was observed 
with no therapy. She was admitted to University Hospital “Merkur” in June, 2002 for the 
evaluation of a newly developed leukocytosis. Laboratory studies revealed a white blood cell 
(WBC) count of 127 x 109/L (myeloblasts 49%, promyelocytes 19%, lymphocytes 18%, 
monocytes 9%, promonocytes 5%), hemoglobin of 77 g/L, platelet count of 86 x 109/L, 
lactate dehydrogenase of 1013 U/L. The cytological bone marrow smear revealed 
approximately 10% of atypical blasts type I, approximately 80% blasts type II and III, with 
numerous granules, somewhere basophile-like, and with some Auer rods (Figure 1.a). Two 
cell populations were found by flow cytometric analysis; one with phenotypic characteristics 
of B-cell CLL: CD5/CD19+, CD5/CD23+, monoclonal CD19/kappa+ (with a weak 
expression of light chains) and blasts population: MPO+, CD2+, CD13+, CD33+, CD117+, 
HLA D/DR-/+, CD 34-. The results were consistent with mixed cell population within 
lymphocyte gate (Table 1). Approximately 20% of the cells in the lymphocyte “window” had 
the immunophenotypic characteristics of B-cell CLL, (CD19/kappa+ versus CD19/lambda+ 
showing imbalance and supporting clonality) while about 80% of the cells in that gate had 
characteristics of blasts (MPO+), and most probably corresponded to a subpopulation of 
smaller blasts that fitted the window. On the contrary, all the cells in the blasts “window” had 
the immunophenotypic characteristics of acute leukemia blasts, while the B-cell CLL clone 
was not present (Table 1). The cytogenetic analysis from the bone marrow sample did not 
show any chromosomal abnormalities, and the karyotype was: 46, XX [10].  
The second patient was a 59-year-old woman. The previous diagnosis of B-CLL was also 
made in 1998 with a stable clinical course, and was observed without therapy. She referred to 
University Hospital “Merkur” in May 2002 for the evaluation of a progressive leukocytosis.  
WBC count was 104,5 x 109/L (atypical blasts 45%, promyelocytes 9%, band neutrophiles 
1%, lymphocytes 41%, prolymphocytes 3%, and plasma cells 1%), hemoglobin 50,6 g/L, 
platelet count 24 x 109/L. The cytological smear of bone marrow revealed approximately 71% 
of atypical blasts type I and II, and approximately 25% lymphocytes (Figure 1.b). The flow 
cytometric analysis demonstrated a population with distinct immunophenotypic features 
corresponding to B-CLL lymphocytes: CD5/CD19+, CD5/CD23+, monoclonal CD19/kappa+ 
(with a weak expression of light chains), HLA D/DR+, CD 79+. The population of blasts 
co-expressed myeloid lineage markers (MPO+, CD13+, CD33+ CD34+, HLA D/DR+), and B 
lymphoid lineage (CD19+, CD79α+, TdT+). (Table1) Cytogenetic analysis revealed the 
following karyotype: 45, XX, inv (3) (q21q26), -7[20]/46XX [5].  
Both patients with previously untreated CLL followed by AL were female of a similar age, 
with a four-year history of clinically indolent CLL without therapy. Both were referred 
because of the newly developed leukocytosis. The cytological analysis revealed two separate 
processes: B-CLL and AML, confirming the diagnosis of bilineal leukemia. Both ALs had the 
same morphological features consistent with AML M2 by FAB classification. The two ALs 
had different immunophenotypic features. In the first case, the blasts expressed typical 
myeloid markers, while in the second case, the blast shared myeloid and lymphoid lineage 
markers. According to Matutes E. and al., this leukemia could have been considered 
biphenotypic [5]. Also, the co-expression of CD19 and CD13 antigens supports the diagnosis 
of the biphenotypic leukemia.  
Our results support the other authors' suggestions that the use of full panel of monoclonal 
antibodies for immunophenotyping is recommended to provide the information about cell 
heterogeneity, as well as the information of an unexpected second malignancy presence [6, 7]. 
Although CLL/AML mixed leukemia is considered very rare, it is possible that the routine use 
of flow cytometric studies nowadays could affect or modify the epidemiological data. It is 
possible that CLL, which can initially be asymptomatic, was not diagnosed in more cases 
presenting with acute leukemia then conventionally expected. Newly developed blast clone 
could have overgrown previously present CLL clone and relatively reduce lymphocyte mass. 
Therefore, reduced lymphocyte population could be considered as non-neoplastic in routine 
morphological analysis, or in flow cytometry focused on acute leukemia panel.  It is possible 
that the routine use of flow cytometric studies and broad panel of monoclonal antibodies 
against mature and immature myeloid and lymphoid markers could reveal higher incidence of 
diagnosis of CLL/AL concomitant leukemia than is believed today.  
The etiology of CLL/AL mixed leukemia is not clear [8, 9]. The development of a second 
acute leukemia in patients with stable CLL suggests the appearance of a new leukemogenic 
factor. The common characteristics of our patients were the time cluster and the fact that they 
had both lived at the border of the war area under air strikes. They have been potentially 
exposed to various toxic agents associated with the military activity in the region. It is known 
that depleted uranium (DU) has been used in the Balkan War. The potential radiotoxic 
properties of DU are the subject of controversy. DU has been identified as an oncogene-
inducing factor by in vitro studies, as well as in animal models [10, 11]. On the contrary, the 
epidemiological studies among the Gulf War veterans and UN soldiers did not confirm its 
cancerogenic potential [12, 13]. Although the hematopoetic system is very sensitive to 
radiation exposure, the conducted studies have not found an increased incidence of 
hematologic malignancies among the children or soldiers potentially exposed to DU [12, 14]. 
Our patients suffering from a rare leukemia shared a few important epidemiological 
characteristics, among them the possible exposure to DU. We hope that this fact could add to 
recent debates on the possible role of depleted uranium (DU) in leukemogenesis.   
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Table 1. Immunophenotypic features of bone marrow lymphocytes and blast population of 
patients 
 
 Patient 1 Patient 2 
 Cellular population (%) 
cellular antigen 
lymphocytes  
(12 %) 
blasts (80 %) 
lymphocytes  
(30 %) 
blasts (53 %) 
CD5 45.3 3.0 34.8 18.6 
CD19  19.5 1.0 83.9 56.9 
CD23 52.4 4.4 68.4 11.0 
TdT 0.1 0.3 5.6 19.7 
CD13 50.6 86.0 22.4 60.0 
CD33 32.6 85.4 25.6 35.8 
CD5/CD23 36.1 1.4 26.8 7.2 
KAPPA+ 
CD19+ «weak» 
18.9 0.3 73.7 12.2 
LAMBDA+ 
CD19+ «weak» 
0.6 0.1 1.9 2.1 
CD5/CD19 34.4 0.6 31.3 14.6 
HLA D/DR 49.3 13.9 91.3 89.4 
CD34 0.8 3.0 5.3 71.7 
MPO 78.5 95.8 4.2 20.3 
CD 79α 18.9 0.4 59.5 23.3 
CD117 3.4 38.9 - - 
CD 15 2.7 16.4 - - 
CD19/CD13 - - 2.0 33.7 
CD19/CD33 - - 21.6 18.7 
 Legends to figure: 
Figure 1. The cytological smear of bone marrow (May Grünwald Giemsa, 1000x) 1.a: patient 
1; 1.b: patient 2.  
 
 
 
 
 
 
 
 
 
